Melanoma Institute Australia welcomes new CEO Matthew Browne
9 August 2018
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Matthew, who takes up the position effective immediately, brings to the organisation a wealth of experience in managing organisations involved in health care and major infrastructure projects.
He has been with Melanoma Institute Australia since January 2017, having performed the roles of Chief Financial Officer and Company Secretary, and more recently Acting CEO. Prior to joining Melanoma Institute Australia, Matthew was Acting CEO for Cure Brain Cancer Foundation and held a variety of senior executive roles responsible for Transport NSW’s Opal smartcard ticketing project, including Director of Ticketing.
Matthew holds a Bachelor of Economics from Macquarie University and has been a member of the Institute of Chartered Accountants in Australia since 1990.
Chairman of Melanoma Institute Australia, Mr Grant King said; “We are excited to welcome Matthew as CEO of Melanoma Institute Australia as his leadership skills and experience in the medical research and not for profit sectors will ensure the organisation continues to be a world leader in melanoma prevention, treatment and cure.”
“Given Matthew’s previous executive roles, including at Melanoma Institute Australia, we are confident his transition into the CEO role will be smooth and effective and the organisation will continue its momentum towards its mission of zero deaths from melanoma,” he said.
“I am delighted and honoured to be leading such a world-class organisation,” Matthew Browne said. “I am proud of the achievements made by Melanoma Institute Australia over many years, providing patients with melanoma the very best standard of care and more life-saving treatment options.
“Melanoma Institute Australia is deeply committed to achieving its mission, and it will truly be a time to celebrate when that day arrives,” he said.
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | jennifer.durante@melanoma.org.au
Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
Australia's best minds in melanoma research converge on Melbourne
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
Nobel Prize for novel cancer therapies
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
World Health Organisation launches 4th edition of Classification of Skin Tumours
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Support PBS listing for pembrolizumab
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Melanoma in Practice: Nurse Conference
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
Reducing the risk of melanoma in young adults
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia launches free e-learning education portal
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
David Day and a lifetime of missed moments
When David lost his life last year, he was 33, with three daughters under six.
Australian melanoma experts share latest breakthroughs with world's best oncologists
ASCO 2018 brings together the world's best in oncology from around the world.
ASCO 2018 – the important role of clinical trials
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
MIA Scoops Awards at the International Academy of Pathology
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Updated Clinical Guidelines for Melanoma
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
Melanoma and Marital Status: A Study
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
A weekend in Paris talking all things pathology...
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Our own 'Australian Story'
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.